Analysis

Hedge Fund Drug Patent Challenges In Doubt After Bass' Test

Law360, New York (March 31, 2017, 3:37 PM EDT) -- Hedge fund manager Kyle Bass' controversial campaign against drug patents appears all but over, and despite some victories at the Patent Trial and Appeal Board, a lack of apparent success betting against pharmaceutical companies' stock has raised doubts about whether similar attacks will continue.

In March, nXn Partners LLC — an analytics company led by Bass' colleague, Erich Spangenberg — issued a final report analyzing the work of the Coalition for Affordable Drugs, a group created by the two men to spearhead the effort to take down drug patents they saw as weak or abusive.

The final result: the Coalition for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS